News

IP Group Australia, a leading specialist in university research commercialisation, announced today that Associate Professor Jason Lee will be joining the company as a fellow under the Researcher Exchange and Development within Industry (REDI) Fellowship Program.

The $32 million REDI Fellowship Program is supported by MTPConnect’s REDI initiative funded by the Medical Research Future Fund (MRFF).

The REDI Fellowship program provides financial support to companies in the medical technology, biotechnology and pharmaceuticals sector to bring researchers, clinicians and MTP professionals in-house for up to 12 months to work on priority medical research projects.

Professor Lee will undertake a 12-month project with IP Group Australia to enhance his research commercialisation skills. He will be embedded in a team of investment managers, assessing opportunities from across top research institutions in Australia, and collaborate in creating and supporting a portfolio of spin-out companies.

Professor Lee is a cancer epigeneticist and currently the head of the Epigenetics and Disease Laboratory at QIMR Berghofer, as well as an Adjunct Associate Professor at the University of Queensland and the Queensland University of Technology.

Prior to this, he was a QIMR International Research Fellow, a Research Professor and Postdoctoral Fellow at the Seoul National University in South Korea, and a Research Associate at Harvard Medical School.

He has also published numerous papers in top tier international medical journals, including Molecular Cell, Proceedings of the National Academy of Science, American Journal of Human Genetics, Nature Genetics, Immunity and Cell Reports.

Professor Lee said: “The REDI Fellowship is a unique opportunity for me to spend a significant period of time in the industry.

“I will be joining IP Group Australia for 12 months as an investment analyst where I will have hands-on experience on the live opportunity assessment and funding process, which is inaccessible in an academic environment.

“Over the course of the fellowship, I will be able to not only share my insights as a cancer biologist with other investment analysts but also develop industry skills that can increase the prospect of commercial translation of research findings.”

Dr Siro Perez, Head of Life Sciences at IP Group Australia, said: “We are delighted to welcome Jason to IP Group Australia as a fellow under the REDI Fellowship Program.

“Jason’s extensive expertise within the field of cancer epigenetics and transcriptional regulation will make a valuable contribution in creating and supporting university spin-out companies.

“We would like to thank the MTPConnect and the Medical Research Future Fund (MRFF) for funding and facilitating this important program.” 

- ENDS -

Media contact:  Aileen Bodart, Cannings Strategic Communications, +61 432 160 136

About IP Group

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc. In Australia and New Zealand, IP Group works in close partnership with the Go8 Universities and the University of Auckland to identify ground-breaking technologies rooted in hard science, which have the most promising commercial potential. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.  For more information, please visit our website at www.ipgroupanz.com.